1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,975 | 1,040 | 21.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen gibt bekannt, dass Adcendo ApS die Antikörperoption ausübt, um die ADC-Entwicklung zu beschleunigen | 291 | Business Wire | Adcendo übt seine Option aus, die vollständig humanen Antikörper von Biocytogen zu nutzen, um seine ADC-Pipeline für Krebserkrankungen mit hohem ungedecktem medizinischen Bedarf weiter auszubauen... ► Artikel lesen | |
| Mo | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development | 192 | Business Wire | Adcendo exercises its option to utilize Biocytogen's fully human antibodies to further expand its ADC pipeline for cancers with high unmet medical need
This collaboration further validates... ► Artikel lesen | |
| 11.11. | Ideaya pushes ahead with Biocytogen bispecific ADC bet | 2 | FierceBiotech | ||
| 11.11. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Announces IDEAYA's Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise | 261 | Business Wire | IDEAYA has exercised the option for an exclusive worldwide license on Biocytogen's potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody-drug conjugate (BsADC), BCG034 (IDE034)... ► Artikel lesen | |
| 11.11. | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT IDEAYA'S NOMINATION OF DEVELOPMENT CANDIDATE IDE034, A POTENTIAL FIRST-IN-CLASS B7H3/PTK7 TOPO-I-PAYLOAD ... | 3 | HKEx | ||
| BIOCYTOGEN PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 25.09. | BIOCYTOGEN-B (02315): 2024 INTERIM REPORT | 1 | HKEx | ||
| 28.08. | BIOCYTOGEN-B (02315): ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2024 | - | HKEx | ||
| 16.08. | BIOCYTOGEN-B (02315): DATE OF BOARD MEETING | 1 | HKEx | ||
| 07.08. | BIOCYTOGEN-B (02315): ANNOUNCEMENT ON PRELIMINARY FINANCIAL DATA FOR THE SIX MONTHS ENDED JUNE 30, 2024 | 1 | HKEx | ||
| 31.07. | IDEAYA in license agreement with Biocytogen for antibody drug conjugate program | 1 | Seeking Alpha | ||
| 31.07. | Ideaya, eyeing drug combos, bags option on Biocytogen bispecific ADC in $400M deal | 2 | FierceBiotech | ||
| 31.07. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program | 298 | Business Wire | Biocytogen granted IDEAYA an option for an exclusive worldwide license for potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate (BsADC) program
B7H3/PTK7... ► Artikel lesen | |
| 31.07. | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT ENTERS INTO OPTION AND LICENSE AGREEMENT WITH IDEAYA FOR POTENTIAL FIRST-IN-CLASS B7H3/PTK7 TOPO-I-PAYLOAD ... | 2 | HKEx | ||
| 16.07. | SOTIO partners with Biocytogen to expand ADC oncology pipeline | 2 | Pharmaceutical Technology | ||
| 16.07. | Sotio taps Biocytogen to create bispecific ADCs in $326M deal | 1 | FierceBiotech | ||
| 16.07. | SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline | 292 | Business Wire | Option and license agreement includes multiple fully human bispecific antibodies generated with Biocytogen's proprietary RenLite platform Agreement will enable SOTIO to significantly broaden... ► Artikel lesen | |
| 16.07. | SOTIO Biotech: SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline | 272 | Business Wire | Option and license agreement includes multiple fully human bispecific antibodies generated with Biocytogen's proprietary RenLite platform Agreement will enable SOTIO to significantly broaden... ► Artikel lesen | |
| 16.07. | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT ENTERS INTO MULTI-TARGET ANTIBODY AGREEMENT WITH SOTIO | 2 | HKEx | ||
| 21.06. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen erhält US-Patent für seine gemeinsame Leichtketten-Mausplattform RenLite | 437 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) gab jetzt die Erteilung eines Patents durch das United States Patent and Trademark Office (USPTO) für die von Biocytogen... ► Artikel lesen | |
| 21.06. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Awarded U.S. Patent for RenLite Common Light Chain Mouse Platform | 298 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced United States Patent and Trademark Office (USPTO) patent grant for independently developed RenLitefully human common... ► Artikel lesen |
Seite:
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 1,000 | -2,80 % | Medigene treibt MDG1015 voran: Studien-Antrag bei EMA | Medigene hat bei der Europäischen Arzneimittelagentur (EMA) einen Antrag auf Genehmigung einer klinischen Prüfung für das MDG1015-Programm eingereicht. Die Phase-1-Studie EPITOME1015-I soll mit einer... ► Artikel lesen | |
| BIOFRONTERA | 2,205 | -1,12 % | PTA-News: Biofrontera AG: Biofrontera berichtet über die Ergebnisse der ersten neun Monate des Jahres 2024 | DJ PTA-News: Biofrontera AG: BIOFRONTERA BERICHTET ÜBER DIE ERGEBNISSE DER ERSTEN NEUN MONATE DES JAHRES 2024
Unternehmensmitteilung für den Kapitalmarkt
Leverkusen (pta/29.11.2024/17:00)... ► Artikel lesen | |
| CLINUVEL | 6,905 | -0,36 % | CLINUVEL PHARMACEUTICALS LIMITED: Revised Securities Trading Policy | ||
| EDITAS MEDICINE | 1,287 | +1,26 % | JPMorgan Downgrades Editas Medicine, Says Focus Shift Sparks Investor Caution | ||
| BLUEBIRD BIO | 8,140 | -0,06 % | bluebird bio Announces 1-for-20 Reverse Stock Split | SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today announced that it will proceed with a 1-for-20 reverse stock split ("Reverse Stock... ► Artikel lesen | |
| ASEP MEDICAL | 0,031 | -1,88 % | Asep Medical wird in landesweit ausgestrahlter Dokumentarreihe präsentiert | Asep wurde für eine spezielle Dokumentarreihe mit dem Titel "Empowered, Hosted by Meg Ryan"
ausgewählt, bei der Führungspersonen aus Wissenschaft, Technologie und Medizin im Blickpunkt stehen.
... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 4,225 | +3,30 % | Cardiff Oncology CFO James Levine erwirbt Aktien im Wert von 36.725 US-Dollar | ||
| CELLECTAR BIOSCIENCES | 0,230 | +1,77 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring | Evaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data and a substantial market opportunity Focusing on advancing radiotherapeutic assets including... ► Artikel lesen | |
| CLEAN HARBORS | 220,60 | -0,18 % | Clean Harbors Aktie: Eingetrübte Investorenstimmung | Die Clean Harbors Aktie verzeichnet in den letzten Handelswochen eine signifikante Abwärtsbewegung. Der Aktienkurs des US-amerikanischen Umweltdienstleisters notiert aktuell bei 230,53 USD, was einem... ► Artikel lesen | |
| SPERO THERAPEUTICS | 0,927 | +0,98 % | What 4 Analyst Ratings Have To Say About Spero Therapeutics | ||
| MESOBLAST | 1,370 | -0,72 % | Mesoblast Limited: Mesoblast's RYONCIL is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy | RYONCIL (remestemcel-L) is the first MSC product approved by FDA for any indication.RYONCIL is the first FDA-approved therapy for children aged 2 months and older, including adolescents and teenagers... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 0,260 | -4,41 % | CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES FIRST PATIENT ENROLLED IN THE GLOBAL MULTICENTER PHASE IB CLINICAL TRIAL OF CS5001 ... | ||
| PROTALIX BIOTHERAPEUTICS | 1,659 | -1,43 % | Chiesi Global, Protalix Announce EMA Validation Of Variation Submission For Pegunigalsidase Alfa | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Chiesi Global Rare Diseases, a unit of Chiesi Group, and Protalix BioTherapeutics announced the European Medicines Agency has validated the Variation Submission... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 12,250 | +3,90 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 17.12.2024 | Das Instrument 14B NO0010776990 HUDDLY AS -,000625 EQUITY wird ex Kapitalmassnahme gehandelt am 17.12.2024 The instrument 14B NO0010776990 HUDDLY AS -,000625 EQUITY is traded ex capital adjustment on... ► Artikel lesen | |
| PURPLE BIOTECH | 3,380 | -4,25 % | Purple Biotech Ltd.: Purple Biotech Reports Third Quarter 2024 Financial Results | Topline data from Phase 2 CM24 pancreatic cancer trial expected by the end of 2024 New CM24 biomarkers data presented during the third quarter of 2024 including two predicting serum biomarkers identified... ► Artikel lesen |
BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,920 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD finden Sie auf Wallstreet Online.
